ADC Therapeutics SA registered up to 61,000,000 common shares for resale, covering 12,911,347 shares and 48,088,653 shares issuable from pre-funded warrants sold to institutional investors in the October 7, 2026 private placement.
ADCT · ADC Therapeutics SA
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.30
- Open
- $1.33
- Day range
- $1.29–1.41
- 52-week closing range
- $0.96–4.88
- Average volume, 30 days
- 1.4M
- Short interest
- 6.4M · 5.0% of shares · 6.7 days
- Short volume, last session
- 70%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- May 2020 to Nov 2026
Up next
Latest documents
ADC Therapeutics reported that Phase 3 LOTIS-5 showed significantly improved progression-free survival with ZYNLONTA plus rituximab versus R-GemOx in 420 patients; median PFS was 6.14 months versus 4.73 months.
ADC Therapeutics reported third-quarter net product revenue of $21.0 million and net loss of $25.3 million. Its October 2026 restructuring included an $86.6 million PIPE and extends expected cash runway into 2029.
ADC Therapeutics reported ZYNLONTA trials with 88.7% ORR in LOTIS-7 and 93% in marginal zone lymphoma, plus preliminary cash of $189.2 million and an expected runway into 2029.
ADC Therapeutics SA shareholders will vote on redomiciling from Switzerland to Delaware and adopting a certificate of incorporation and bylaws. The first two proposals lapse if redomiciliation is not completed by June 30, 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | $36M | six months ended June 30, 2026 | — |
| Adjusted net loss per share, basic and diluted non-GAAP | $0.23 | Six Months Ended June 30, 2026 | — |
| Adjusted total operating expenses non-GAAP | $80.1M | six months ended June 30, 2026 | — |
| annualized estimated cost savings | $10M | second quarter 2026 | — |
| workforce reduction | 17% | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADCT
this stock
ADC Therapeutics SA
|
$165.97M | -63.2% | +14.9% | — | 5.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.89B | +5.3% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 24
ADC Therapeutics SA registered up to 61,000,000 common shares for resale, covering 12,911,347 shares and 48,088,653 shares issuable from pre-funded warrants sold to institutional investors in the October 7, 2026 private placement.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADCT | -7.8% | -18.8% | -61.8% | -15.0% | -63.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -2.4% | -12.5% | -56.1% | -9.8% | -68.2% |